Marksans Pharma · NSE: MARKSANS · BSE: 524404
Q1 FY25 results · Apr–Jun 2024
Marksans Pharma reported revenue from operations of ₹590.62 crore (up 18.1% from Q1 FY24) and net profit of ₹89.07 crore (up 26.4% from Q1 FY24) for Q1 FY25 (Apr–Jun 2024), on a consolidated basis.
| Item | Q1 FY25 | Q1 FY24 | YoY | Q4 FY24 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 590.62 | 500.03 | +18.1% | 560.01 | +5.5% |
| Other income | 14.95 | 10.10 | +48.1% | 16.53 | −9.6% |
| Total income | 605.57 | 510.13 | +18.7% | 576.54 | +5.0% |
| Profit before tax | 120.02 | 96.83 | +24.0% | 100.28 | +19.7% |
| Net profit for the period | 89.07 | 70.44 | +26.4% | 77.64 | +14.7% |
| Attributable to shareholders of the company | 88.75 | 68.66 | +29.3% | 72.66 | +22.1% |
| EPS, basic (₹) | 1.96 | 1.52 | +28.9% | 1.73 | +13.3% |
| Net margin (%) | 15.1 | 14.1 | 13.9 |
| Item | Q1 FY25 | Q1 FY24 | YoY | Q4 FY24 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 254.53 | 182.04 | +39.8% | 225.20 | +13.0% |
| Other income | 8.15 | 32.62 | −75.0% | 12.19 | −33.1% |
| Total income | 262.68 | 214.66 | +22.4% | 237.39 | +10.7% |
| Profit before tax | 42.30 | 54.40 | −22.2% | 38.40 | +10.2% |
| Net profit for the period | 32.02 | 44.19 | −27.6% | 32.99 | −3.0% |
| EPS, basic (₹) | 0.71 | 0.98 | −27.6% | 0.73 | −2.7% |
| Net margin (%) | 12.6 | 24.3 | 14.7 |
Consolidated
- Filed with BSE
- 14 Aug 2024, 16:15 IST
- Board meeting
- 13 Aug 2024
- Period
- 01 Apr 2024 to 30 Jun 2024
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 14 Aug 2024, 16:15 IST
- Board meeting
- 13 Aug 2024
- Period
- 01 Apr 2024 to 30 Jun 2024
- Review status
- Unaudited
- Source
- XBRL filing on BSE